Latest News and Press Releases
Want to stay updated on the latest news?
-
Basel, 25. Juni 2015 - Basilea Pharmaceutica AG (SIX: BSLN) gab heute den Beginn einer klinischen Phase-1/2a-Studie mit einer oralen Darreichungsform ihres Krebsmedikamentenkandidaten BAL101553...
-
Basel, Switzerland, June 25, 2015 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today the start of a clinical phase 1/2a study with an oral formulation of its anti-cancer drug candidate...
-
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} This press release is also available in French...
-
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} This press release is also available in French...
-
Lors de l'Assemblée générale ordinaire de CI COM SA, Genève, qui s'est tenue le 19 juin 2015 à Genève, les actionnaires ont approuvé l'ensemble des propositions du Conseil d'administration. Le...
-
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} The ordinary shareholders meeting of...
-
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Die ordentliche Generalversammlung vom...
-
Liestal, Schweiz, 22. Juni 2015 - Santhera Pharmaceuticals (SIX: SANN) gibt die Ernennung von Christoph Rentsch zum Chief Financial Officer bekannt. Mit Wirkung zum 1. Juli 2015 ernennt Santheras...
-
Liestal, Switzerland, June 22, 2015 - Santhera Pharmaceuticals (SIX: SANN) announces the appointment of Christoph Rentsch as Chief Financial Officer. With effect from July 1, 2015, the Santhera...
-
Glatopa is the first FDA-approved, substitutable generic version of Copaxone® 20mg, a treatment for relapsing forms of multiple sclerosis Sandoz has begun shipping to US...